Epic Sciences
| Site | |
|---|---|
| Stage of funding: | Current |
| Therapeutic group: | Oncology |
| Type: | Diagnostic |
Description
Epic Sciences, Inc. is developing novel diagnostics to personalize and advance the treatment and management of cancer. Epic’s mission is to enable the rapid and non-invasive detection of genetic and molecular changes in cancer throughout a patient’s journey.
The company was founded on a powerful platform to identify and characterize rare cells, including CTCs. Epic's technology helps match patients to targeted therapies and monitor for drug resistance, so that the best treatment path can be chosen at every clinical decision point.
Today, Epic partners with leading pharmaceutical companies and major cancer centers around the world. Epic’s goal is to commercialize the Company's technology to increase the success rate of cancer drugs in clinical trials and improve patient outcomes by providing physicians real-time information to guide treatment choices.
Portfolio companies news
-
Clearside Biomedical, Inc. (“Clearside”), (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from PEACHTREE, its pivotal Phase 3 trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, will be shared as a late-breaking oral presentation during the 2018 annual meeting of the American Society of Retina Specialists , July 20-25 in Vancouver, Canada .
-
11 July 2018
Clearside Biomedical Appoints Carol Hoang as Vice President, Medical Affairs
-
10 July 2018
Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer
-
21 June 2018
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index